These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 2738408)

  • 1. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T; Chang AE; Shu SY
    J Immunol; 1988 Apr; 140(7):2453-61. PubMed ID: 2450925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
    Chou T; Bertera S; Chang AE; Shu S
    J Immunol; 1988 Sep; 141(5):1775-81. PubMed ID: 3261761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
    Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T; Krinock RA; Chang AE; Shu S
    Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S; Chou T; Rosenberg SA
    J Immunol; 1986 May; 136(10):3891-8. PubMed ID: 3486223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of newly induced murine sarcomas.
    Shu SY; Rosenberg SA
    Cancer Res; 1985 Apr; 45(4):1657-62. PubMed ID: 3872168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of antitumor reactivity in regional draining lymph nodes from tumor-immunized and tumor-bearing murine hosts.
    Stephenson KR; Perry-Lalley D; Griffith KD; Shu S; Chang AE
    Surgery; 1989 Apr; 105(4):523-8. PubMed ID: 2928954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
    Kagamu H; Shu S
    J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.